Louisiana Department of Health Informational Bulletin



To:AmeriHealth Caritas Louisiana ProvidersDate:March 2, 2022Subject:Informational Bulletin 22-5: Pharmacy Brand Name and Generic
Drugs Policy

Informational Bulletins that summarize policies and/or procedures are intended for quick reference and are accurate on the date they are issued.

Claims for multi-source "Brand Name Products" that are not included in the PDL/NPDL process (i.e., drugs not listed on the Preferred Drug List on the static link), do not require prior authorization.

AmeriHealth Caritas Louisiana allows dispense as written (DAW) codes "1", "5" "8", and "9" for brand name processing. The following codes must accommodate the filling of a brand name product without use of prior authorization:

- DAW "1": Brand name medically necessary from prescriber
- DAW "5": Substitution allowed-brand drug dispensed as a generic (should be allowed when the brand drug is less expensive for 340B providers)
- DAW "8": Substitution allowed, generic drug not available in marketplace
- DAW "9": Preferred brand over generic drugs

Denials of brand drugs (unless the brand is a preferred drug) should deny with an error code stating "generic substitution required".

This information will be included in the <u>AmeriHealth Caritas Louisiana Provider Handbook</u> by **March 15, 2022**.

Questions regarding this message should be directed to AmeriHealth Caritas Louisiana Provider Services at 1-888-922-0007. The Provider Services Department can be reached between 7:00 am – 7:00 pm daily.

You can find a complete listing of Informational Bulletins on the <u>Provider Newsletters and</u> <u>Updates</u> page of our website under the header <u>Louisiana Department of Health Information</u> <u>Bulletins</u>.

Need to update your provider information? Send full details to: <u>network@amerihealthcaritasla.com</u>.